文献速递消化系统肿瘤

利用二代测序超选择转移性结直肠癌患者以提高抗EGFR治疗临床疗效

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
PubMed 文献 · Ann Oncol · 2019-01-01

研究对581份未经治疗的转移性结直肠癌肿瘤样本进行突变分析,比较5%灵敏度标准检测与1%灵敏度二代测序。380份可评估样本中,二代测序检出RAS、BRAFV600E或PIK3CA突变率69.21%,高于标准检测的56.05%(P=0.00018)。将检测阈值从5%降至1%并未改善抗EGFR治疗的患者选择,但四重野生型肿瘤患者抗EGFR疗效显著更好。

要点

  • 二代测序1%阈值较标准5%阈值检出更多突变(69.21% vs 56.05%,P=0.00018)。
  • 将突变检测阈值从5%调整至1%未改善抗EGFR治疗的患者选择。
  • 四重野生型肿瘤患者接受抗EGFR治疗的缓解率、无进展生存和总生存均更优。

核心结论

  • 将组织样本突变检测阈值从5%突变等位基因分数调整至1%未改善抗EGFR治疗的患者选择。
  • 四重野生型肿瘤患者抗EGFR治疗缓解显著更好。

研究设计与样本

  • 收集来自7项临床研究的581份未经治疗转移性结直肠癌患者肿瘤样本。
  • 采用标准治疗检测(therascreen pyro,灵敏度5%突变等位基因分数)与二代测序技术(454GS Junior平台,灵敏度1%)进行突变分析。
  • 质量评估后380份样本可评估用于分子分析。

主要发现

  • 标准治疗突变分析在56.05%样本中检出RAS、BRAFV600E或PIK3CA突变,二代测序检出率为69.21%(P=0.00018)。
  • 二代测序在263例突变病例中的96例(36.5%;范围2-7)识别出多个低频突变等位基因共存。
  • 按标准治疗检测,RAS野生型、RAS/BRAF野生型或四重(KRAS/NRAS/BRAF/PIK3CA)野生型肿瘤患者接受抗EGFR治疗的缓解率、无进展生存和总生存逐步改善。
  • 将二代测序检测阈值提高至1%未观察到缓解率、无进展生存或总生存的额外获益。
  • 二代测序检测到的最常见突变其突变等位基因分数与抗EGFR缓解呈负相关(P=0.039)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended RAS analysis is mandatory in metastatic colorectal cancer (mCRC) patients. The optimal threshold of RAS mutated subclones to identify patients most likely to benefit from antiepidermal growth factor receptor (EGFR) therapy is controversial. Our aim was to assess the clinical impact of detecting mutations in RAS, BRAF, PIK3CA and EGFRS492R in basal tissue tumour samples by using a highly sensitive next-generation sequencing (NGS) technology in mCRC patients treated with chemotherapy plus anti-EGFR or anti-vascular endothelial growth factor. PATIENTS AND METHODS: Five hundred and eighty-one tumour samples from untreated mCRC patients from 7 clinical studies were collected. Mutational analysis was carried out by standard-of-care (therascreen pyro) with a sensitivity detection of 5% mutant allele fraction (MAF), and compared with NGS technology using 454GS Junior platform (Roche Applied Science, Germany) with a sensitivity of 1%. Molecular results were correlated with clinical outcomes. RESULTS: After quality assessment, 380 samples were evaluable for molecular analysis. Standard-of-care mutational analysis detected RAS, BRAFV600E or PIK3CA mutations in 56.05% of samples compared with 69.21% by NGS (P = 0.00018). NGS identified coexistence of multiple low-frequency mutant alleles in 96 of the 263 mutated cases (36.5%; range 2-7). Response rate (RR), progression-free survival (PFS) and overall survival (OS) were increasingly improved in patients with RAS wild-type, RAS/BRAF wild-type or quadruple (KRAS/NRAS/BRAF/PIK3CA) wild-type tumours treated with anti-EGFR, assessed by standard-of-care. No additional benefit in RR, PFS or OS was observed by increasing the detection threshold to 1% by NGS. An inverse correlation between the MAF of the most prevalent mutation detected by NGS and anti-EGFR response was observed (P = 0.039). EGFRS492Rmutation was not detected in untreated samples. CONCLUSIONS: No improvement in the selection of patients for anti-EGFR therapy was obtained by adjusting the mutation detection threshold in tissue samples from 5% to 1% MAF. Response to anti-EGFR was significantly better in patients with quadruple wild-type tumours.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Vidal J, Bellosillo B, Santos Vivas C, et al. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Ann Oncol. 2019. PMID: 30689692. doi:10.1093/annonc/mdz005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。